Log in

Celsion Stock Price, News & Analysis (NASDAQ:CLSN)

$1.71
+0.02 (+1.18 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$1.69
Now: $1.71
$1.75
50-Day Range
$1.52
MA: $1.72
$1.83
52-Week Range
$1.35
Now: $1.71
$2.72
Volume84,421 shs
Average Volume126,162 shs
Market Capitalization$36.58 million
P/E RatioN/A
Dividend YieldN/A
Beta1.9
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLSN
CUSIPN/A
Phone609-896-9100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$500,000.00
Book Value$1.11 per share

Profitability

Net Income$-11,880,000.00
Net Margins-1,489.20%

Miscellaneous

Employees29
Market Cap$36.58 million
Next Earnings Date11/13/2019 (Estimated)
OptionableOptionable

Receive CLSN News and Ratings via Email

Sign-up to receive the latest news and ratings for CLSN and its competitors with MarketBeat's FREE daily newsletter.


Celsion (NASDAQ:CLSN) Frequently Asked Questions

What is Celsion's stock symbol?

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

When did Celsion's stock split? How did Celsion's stock split work?

Celsion shares reverse split on Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

How were Celsion's earnings last quarter?

Celsion Co. (NASDAQ:CLSN) released its earnings results on Wednesday, August, 14th. The biotechnology company reported ($0.29) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.04. The biotechnology company earned $0.13 million during the quarter, compared to analyst estimates of $0.13 million. Celsion had a negative net margin of 1,489.20% and a negative return on equity of 53.40%. View Celsion's Earnings History.

When is Celsion's next earnings date?

Celsion is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Celsion.

What price target have analysts set for CLSN?

2 brokerages have issued twelve-month target prices for Celsion's stock. Their predictions range from $9.00 to $9.00. On average, they expect Celsion's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 426.3% from the stock's current price. View Analyst Price Targets for Celsion.

What is the consensus analysts' recommendation for Celsion?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Celsion.

Has Celsion been receiving favorable news coverage?

Press coverage about CLSN stock has trended somewhat negative recently, InfoTrie reports. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Celsion earned a daily sentiment score of -1.5 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Celsion.

Who are some of Celsion's key competitors?

What other stocks do shareholders of Celsion own?

Who are Celsion's key executives?

Celsion's management team includes the folowing people:
  • Mr. Michael H. Tardugno, Exec. Chairman, Pres & CEO (Age 68)
  • Mr. Jeffrey W. Church CPA, CPA, CFO, Exec. VP & Corp. Sec. (Age 62)
  • Dr. Khursheed Anwer, Exec. VP & Chief Scientific Officer (Age 59)
  • Dr. Nicholas Borys, Exec. VP & Chief Medical Officer (Age 60)
  • Mr. Timothy J. Tumminello, Chief Accounting Officer & Controller (Age 61)

How do I buy shares of Celsion?

Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Celsion's stock price today?

One share of CLSN stock can currently be purchased for approximately $1.71.

How big of a company is Celsion?

Celsion has a market capitalization of $36.58 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-11,880,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. Celsion employs 29 workers across the globe.View Additional Information About Celsion.

What is Celsion's official website?

The official website for Celsion is http://www.celsion.com/.

How can I contact Celsion?

Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at 609-896-9100 or via email at [email protected]


MarketBeat Community Rating for Celsion (NASDAQ CLSN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  351 (Vote Outperform)
Underperform Votes:  271 (Vote Underperform)
Total Votes:  622
MarketBeat's community ratings are surveys of what our community members think about Celsion and other stocks. Vote "Outperform" if you believe CLSN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLSN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel